HKMPF - FDA OKs Hikma's Kloxxado nasal spray in opioid overdose

The FDA has approved Hikma Pharmaceuticals' (HKMPF) Kloxxado (naloxone hydrochloride) nasal spray 8mg, for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression, for adult and pediatric patients. Kloxxado contains twice as much naloxone per spray as Narcan Nasal Spray 4mg nasal spray to reverse the effects of opioid overdose. Hikma expects Kloxxado to be available in H2 2021. Narcan is a registered trademark of ADAPT Pharma Operations Limited.

For further details see:

FDA OKs Hikma's Kloxxado nasal spray in opioid overdose